Glycemic Control and Adverse Clinical Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus: Results from KNOW-CKD

BACKGROUND: The optimal level of glycosylated hemoglobin (HbA1c) to prevent adverse clinical outcomes is unknown in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). METHODS: We analyzed 707 patients with CKD G1-G5 without kidney replacement therapy and T2DM from the Ko...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Ga Young, Koh, Hee Byung, Kim, Hyung Woo, Park, Jung Tak, Yoo, Tae-Hyun, Kang, Shin-Wook, Kim, Jayoun, Kim, Soo Wan, Kim, Yeong Hoon, Sung, Su Ah, Oh, Kook-Hwan, Han, Seung Hyeok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404520/
https://www.ncbi.nlm.nih.gov/pubmed/37096377
http://dx.doi.org/10.4093/dmj.2022.0112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404520/
https://www.ncbi.nlm.nih.gov/pubmed/37096377
http://dx.doi.org/10.4093/dmj.2022.0112

Ejemplares similares